Maximus (NYSE:MMS – Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 7.900-8.200 for the period, compared to the consensus EPS estimate of 8.430. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.3 billion.
Analysts Set New Price Targets
A number of equities analysts have issued reports on MMS shares. Weiss Ratings cut Maximus from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 20th. Zacks Research cut Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Finally, Wall Street Zen downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.
Read Our Latest Stock Report on MMS
Maximus Stock Performance
Maximus (NYSE:MMS – Get Free Report) last announced its earnings results on Thursday, August 6th. The health services provider reported $2.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.01. Maximus had a return on equity of 24.91% and a net margin of 7.07%.The business had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.33 billion. During the same period last year, the company earned $2.16 EPS. Maximus’s revenue for the quarter was down 5.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. Sell-side analysts forecast that Maximus will post 8.05 EPS for the current year.
Maximus Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Friday, August 14th will be paid a $0.33 dividend. This represents a $1.32 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, August 14th. Maximus’s payout ratio is currently 19.76%.
Maximus News Summary
Here are the key news stories impacting Maximus this week:
- Positive Sentiment: Fiscal Q3 adjusted earnings were $2.22 per share, ahead of analyst estimates of approximately $2.20–$2.21 and up from $2.16 a year earlier. Higher margins also supported the quarter’s bottom-line performance. Maximus Q3 Earnings Beat Estimates, Increase Year Over Year
- Positive Sentiment: The earnings beat, year-over-year EPS growth and stronger margins indicate that Maximus is maintaining profitability even as sales soften. Maximus Q3 Earnings Beat Estimates
- Neutral Sentiment: Management’s fiscal Q3 earnings call focused on the quarterly performance and updated outlook, providing investors with additional context on operating trends and the company’s expectations for the remainder of fiscal 2026. Maximus Q3 2026 Earnings Call Transcript
- Negative Sentiment: Revenue was $1.28 billion, below the $1.33 billion consensus estimate and down 5.1% year over year. The shortfall suggests softer demand or project timing is limiting growth. Maximus Fiscal Q3 Earnings Snapshot
- Negative Sentiment: Maximus reduced fiscal 2026 EPS guidance to $7.90–$8.20, below the consensus estimate of $8.43. Revenue guidance of $5.2–$5.4 billion remains broadly in line with expectations at the midpoint, but the lower profit outlook is a key overhang for MMS. Updated Maximus Fiscal 2026 Guidance
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its position in shares of Maximus by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,965,916 shares of the health services provider’s stock worth $169,700,000 after buying an additional 96,343 shares during the period. Boston Partners lifted its holdings in Maximus by 47.0% in the third quarter. Boston Partners now owns 966,139 shares of the health services provider’s stock valued at $88,236,000 after buying an additional 308,892 shares during the period. Goldman Sachs Group Inc. boosted its position in Maximus by 218.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 583,627 shares of the health services provider’s stock valued at $50,379,000 after acquiring an additional 400,315 shares during the last quarter. Nuveen LLC boosted its position in Maximus by 29.1% during the fourth quarter. Nuveen LLC now owns 534,083 shares of the health services provider’s stock valued at $46,102,000 after acquiring an additional 120,501 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in Maximus by 24.6% during the 3rd quarter. Bank of America Corp DE now owns 453,616 shares of the health services provider’s stock worth $41,447,000 after acquiring an additional 89,693 shares during the period. Institutional investors and hedge funds own 97.21% of the company’s stock.
About Maximus
Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.
Read More
- Five stocks we like better than Maximus
- Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
- AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish
- Why These 3 Equal Weight ETFs Have Outperformed the S&P This Year
- MarketBeat Week in Review – 08/03 – 08/07
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.
